Serum brain‐derived neurotrophic factor and progression to MCI in cognitively normal older adults

IF 13 1区 医学 Q1 CLINICAL NEUROLOGY
Kyungtae Kim, Min Soo Byun, Dahyun Yi, Joon Hyung Jung, Bo Kyung Sohn, Gijung Jung, Hyejin Ahn, Jun‐Young Lee, Yun‐Sang Lee, Yu Kyeong Kim, Dong Young Lee
{"title":"Serum brain‐derived neurotrophic factor and progression to MCI in cognitively normal older adults","authors":"Kyungtae Kim, Min Soo Byun, Dahyun Yi, Joon Hyung Jung, Bo Kyung Sohn, Gijung Jung, Hyejin Ahn, Jun‐Young Lee, Yun‐Sang Lee, Yu Kyeong Kim, Dong Young Lee","doi":"10.1002/alz.088177","DOIUrl":null,"url":null,"abstract":"BackgroundBrain derived neurotropic factor (BDNF) has been associated with improved neuronal survival and synaptic plasticity and long‐term memory. Some human studies also reported the relationship between lower blood BDNF levels and poorer memory function and dementia. A prior longitudinal study also demonstrated higher serum BDNF levels were associated with lower risk of overall dementia and Alzheimer’s disease (AD) dementia. However, it remains uncertain whether reduced serum BDNF levels precede the onset of mild cognitive impairment (MCI), which is known as pre‐dementia stage. This study aimed to examine whether higher serum BDNF in cognitively normal (CN) older adults is related to less common progression to MCI and to identify potential moderators of this relationship.MethodA total of 278 CN older adults between 55 and 90 years of age were enrolled. All participants underwent comprehensive clinical assessments, serum BDNF level measurement, and multimodal brain imaging including Pittsburgh compound B (PIB)‐positron emission tomography (PET) at baseline, and followed up for up to 4 years. Serum BDNF levels were divided into two categories by median value of serum BDNF level: < 21448.5 pg/mL (low BDNF), and > 21448.5 pg/mL (high BDNF). Cox model was used to analyze the relationship between baseline BDNF levels and the risk for MCI progression controlling for potential confounders. We also ran sensitivity analyses stratified by sex, age, education, apolipoprotein E ε4 (APOE4) positivity, and amyloid PET positivity.ResultDuring follow‐up, 24 participants developed MCI. Controlling for age, sex, education and APOE4 positivity, low BDNF group had significantly more frequent progression to MCI than high BDNF group (hazard ratio for MCI, 2.98; 95% CI, 1.17‐7.56; p=0.02) and these association persisted even after controlling for amyloid PET positivity and vascular risk factor score as additional covariates (hazard ratio, 2.98; 95% CI, 1.17‐7.55; p=0.02). Sensitivity analyses revealed that the associations were apparent only among women, participants aged younger than 75 years, those without college degrees, and amyloid negative participants (Table).ConclusionHigher serum BDNF levels may protect against future occurrence of MCI in cognitively healthy older adults. Such influence appears more prominent in women and younger, less educated, or amyloid PET negative individuals.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"20 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.088177","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundBrain derived neurotropic factor (BDNF) has been associated with improved neuronal survival and synaptic plasticity and long‐term memory. Some human studies also reported the relationship between lower blood BDNF levels and poorer memory function and dementia. A prior longitudinal study also demonstrated higher serum BDNF levels were associated with lower risk of overall dementia and Alzheimer’s disease (AD) dementia. However, it remains uncertain whether reduced serum BDNF levels precede the onset of mild cognitive impairment (MCI), which is known as pre‐dementia stage. This study aimed to examine whether higher serum BDNF in cognitively normal (CN) older adults is related to less common progression to MCI and to identify potential moderators of this relationship.MethodA total of 278 CN older adults between 55 and 90 years of age were enrolled. All participants underwent comprehensive clinical assessments, serum BDNF level measurement, and multimodal brain imaging including Pittsburgh compound B (PIB)‐positron emission tomography (PET) at baseline, and followed up for up to 4 years. Serum BDNF levels were divided into two categories by median value of serum BDNF level: < 21448.5 pg/mL (low BDNF), and > 21448.5 pg/mL (high BDNF). Cox model was used to analyze the relationship between baseline BDNF levels and the risk for MCI progression controlling for potential confounders. We also ran sensitivity analyses stratified by sex, age, education, apolipoprotein E ε4 (APOE4) positivity, and amyloid PET positivity.ResultDuring follow‐up, 24 participants developed MCI. Controlling for age, sex, education and APOE4 positivity, low BDNF group had significantly more frequent progression to MCI than high BDNF group (hazard ratio for MCI, 2.98; 95% CI, 1.17‐7.56; p=0.02) and these association persisted even after controlling for amyloid PET positivity and vascular risk factor score as additional covariates (hazard ratio, 2.98; 95% CI, 1.17‐7.55; p=0.02). Sensitivity analyses revealed that the associations were apparent only among women, participants aged younger than 75 years, those without college degrees, and amyloid negative participants (Table).ConclusionHigher serum BDNF levels may protect against future occurrence of MCI in cognitively healthy older adults. Such influence appears more prominent in women and younger, less educated, or amyloid PET negative individuals.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Alzheimer's & Dementia
Alzheimer's & Dementia 医学-临床神经学
CiteScore
14.50
自引率
5.00%
发文量
299
审稿时长
3 months
期刊介绍: Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信